|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ganti AKP, Loo BW, Bassetti M, Blakely C,
Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M,
et al: Small cell lung cancer, version 2.2022, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
19:1441–1464. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Faivre-Finn C, Snee M, Ashcroft L, Appel
W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden
S, et al: Concurrent once-daily versus twice-daily
chemoradiotherapy in patients with limited-stage small-cell lung
cancer (CONVERT): An open-label, phase 3, randomised, superiority
trial. Lancet Oncol. 18:1116–1125. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheng Y, Spigel DR, Cho BC, Laktionov KK,
Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, et al:
Durvalumab after chemoradiotherapy in limited-stage small-cell lung
cancer. N Engl J Med. 391:1313–1327. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Musto L: Improved iron-hematoxylin stain
for elastic fibers. Stain Technol. 56:185–187. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ganti AKP, Loo BW, Bassetti M, Blakely C,
Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M,
et al: Small cell lung cancer, version 2.2022, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
19:1441–1464. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bozcuk H, Artac M, Ozdogan M and Savas B:
Does maintenance/consolidation chemotherapy have a role in the
management of small cell lung cancer (SCLC)? A metaanalysis of the
published controlled trials. Cancer. 104:2650–2657. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou H, Zeng C, Wei Y, Zhou J and Yao W:
Duration of chemotherapy for small cell lung cancer: A
meta-analysis. PLoS One. 8:e738052013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gay CM, de Groot PM, Pietanza MC and Byers
LA: Durable, exceptional response to temozolomide in a patient with
extensive-stage small cell lung cancer (ES-SCLC) metastatic to
brain. Cancer Treatment and Research Communications. 10:17–20.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lukas RV, Vigneswaran J and Salgia R:
Etoposide and temozolomide in combination for the treatment of
progressive small-cell lung cancer central nervous system
metastases: Two cases. Tumori. 99:e73–e76. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Abrey LE, Olson JD, Raizer JJ, Mack M,
Rodavitch A, Boutros DY and Malkin MG: A phase II trial of
temozolomide for patients with recurrent or progressive brain
metastases. J Neurooncol. 53:259–265. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Trinh VA, Patel SP and Hwu WJ: The safety
of temozolomide in the treatment of malignancies. Expert Opin Drug
Saf. 8:493–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hammond LA, Eckardt JR, Baker SD, Eckhardt
SG, Dugan M, Forral K, Reidenberg P, Statkevich P, Weiss GR,
Rinaldi DA, et al: Phase I and pharmacokinetic study of
temozolomide on a daily-for-5-days schedule in patients with
advanced solid malignancies. J Clin Oncol. 17:2604–2613. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dixit S, Baker L, Walmsley V and Hingorani
M: Temozolomide-related idiosyncratic and other uncommon
toxicities: A systematic review. Anticancer Drugs. 23:1099–1106.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li X, Wu D, Tang J and Wu Y: The
efficiency and safety of temozolomide and PD-1/L1 inhibitors in
pretreated NSCLC with brain metastasis: A retrospective cohort. J
Cancer Res Clin Oncol. 150:2712024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Owen DH, Wei L, Benner B, Pilcher C,
Christenson G, Ferguson S, Jukich M, Sukrithan V, Konda B, Shah M,
et al: OA12.04 efficacy of nivolumab and temozolomide in extensive
stage small cell lung cancer after chemo-immunotherapy: A phase 2
trial. J Thorac Oncol. 17:S32–S33. 2022. View Article : Google Scholar
|
|
17
|
Owen DH, Durm GA, Wei L, Pilcher C,
Ferguson S, Benner B, Jukich M, Sukrithan V, Konda B, Savardekar H,
et al: EP14.05–004 temozolomide and atezolizumab as second line
treatment for extensive stage small cell lung cancer: A randomized,
multi-cohort phase 2 trial. J Thorac Oncol. 17:S544–S545. 2022.
View Article : Google Scholar
|
|
18
|
Lok BH, Gardner EE, Schneeberger VE, Ni A,
Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell
SN, et al: PARP inhibitor activity correlates with SLFN11
expression and demonstrates synergy with temozolomide in small cell
lung cancer. Clin Cancer Res. 23:523–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pietanza MC, Waqar SN, Krug LM, Dowlati A,
Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto
J, et al: Randomized, double-blind, phase II study of temozolomide
in combination with either veliparib or placebo in patients with
relapsed-sensitive or refractory small-cell lung cancer. J Clin
Oncol. 36:2386–2394. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chabanon RM, Muirhead G, Krastev DB, Adam
J, Morel D, Garrido M, Lamb A, Hénon C, Dorvault N, Rouanne M, et
al: PARP inhibition enhances tumor cell-intrinsic immunity in
ERCC1-deficient non-small cell lung cancer. J Clin Invest.
129:1211–1228. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sen T, Rodriguez BL, Chen L, Corte CMD,
Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, et al:
Targeting DNA damage response promotes antitumor immunity through
STING-mediated T-cell activation in small cell lung cancer. Cancer
Discov. 9:646–661. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Belgiovine C, Bello E, Liguori M,
Craparotta I, Mannarino L, Paracchini L, Beltrame L, Marchini S,
Galmarini CM, Mantovani A, et al: Lurbinectedin reduces
tumour-associated macrophages and the inflammatory tumour
microenvironment in preclinical models. Br J Cancer. 117:628–638.
2017. View Article : Google Scholar : PubMed/NCBI
|
